Jonathan Smith

Dr. Jonathan Smith is an eminent virologist and currently, Chief Scientific Officer at VLP Therapeutics. He has over thirty-five years of experience in basic virology, infectious disease research, and vaccine development spanning the industry, government and academic laboratories.

Currently, the Chief Scientific Officer at VLP Therapeutics, Dr. Smith brings over 35 years of experience in virology, infectious diseases research and vaccine development with a focus on RNA-replicon vaccines. Dr. Smith was the former Chief of the Department of Virology, United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and co-founder of AlphaVax, Inc., a biotech focused on RNA vaccines for infectious diseases and cancer. He has also held leadership positions at multiple biotech companies including VP for Development, Operations and Research at ClearPath Vaccines, Executive VP and Chief Scientific Officer at PaxVax Inc., and Chief Scientific Officer at Liquidia Technologies. Dr. Smith has led preclinical and translational programs for a range of infectious agents including Klebsiella, Pseudomonas, Cholerae, HIV, Influenza, Chikungunya, Anthrax, Dengue, Malaria and Zika. Dr. Smith has over 100 publications and multiple issued and pending patents in this field.